GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Gabather GABA.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

0.02

+3.88%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Gabather

Its shares trade on Nasdaq Stockholm under the ticker GABA.ST. It has been listed since 3 November 2014. In the fiscal year to 31 December 2021, it reported revenue of −SEK 23,000 and a net loss of SEK 17.0m. At that date it held total assets of SEK 15.4m and shareholders' equity of SEK 11.0m.

Gabather AB engages in the research and development of drug candidates for treatment of diseases affecting the central nervous system. The company is headquartered in Sodertalje, Stockholm. The company went IPO on 2014-11-03. The firm develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The firm mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimer’s disease.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
3 Nov 2014

Leadership

Pay as last reported

  • Dr. Bert JunnoChairman of the Board
  • Dr. Michael-Robin WittChief Executive Officer, Director, since 2018SEK 525,000
  • Ms. Theresa OlsenIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Gabather AB focuses on CNS drug development for anti-psychotics and Alzheimer's treatments.
  • The company's R&D in CNS therapies targets high-demand areas like depression and anxiety.
  • Gabather AB's IPO in 2014 established a strong foundation for pharmaceutical innovation.

Weaknesses

  • Gabather AB's focus on CNS diseases limits diversification across other medical sectors.
  • The company's R&D efforts are concentrated on a narrow therapeutic area without expansion plans.
  • Gabather AB's small-scale operations may hinder rapid market penetration in CNS treatments.

Opportunities

  • Gabather AB can leverage growing global demand for CNS treatments in aging populations.
  • Expanding into Alzheimer's disease therapies presents significant market potential.
  • Collaborations with pharmaceutical giants could accelerate CNS drug development.

Threats

  • Regulatory hurdles in CNS drug approvals pose significant development delays.
  • Intense competition from established pharmaceutical firms in CNS markets.
  • Economic downturns may reduce funding for CNS research and development.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.